These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 27866832)

  • 1. Roscoe Owen Brady, MD: Remembrances of co-investigators and colleagues.
    Desnick RJ; Barton NW; Furbish S; Grabowski GA; Karlsson S; Kolodny EH; Medin JA; Murray GJ; Mistry PK; Patterson MC; Schiffmann R; Weinreb NJ
    Mol Genet Metab; 2017; 120(1-2):1-7. PubMed ID: 27866832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ten plus one challenges in diseases of the lysosomal system.
    Grabowski GA; Whitley C
    Mol Genet Metab; 2017; 120(1-2):38-46. PubMed ID: 27923545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The metabolism of glucocerebrosides - From 1965 to the present.
    Futerman AH; Platt FM
    Mol Genet Metab; 2017; 120(1-2):22-26. PubMed ID: 27955980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment for LSDs: no longer just enzyme replacement therapy for Gaucher disease. Foreword.
    Cohen IJ; Baris H; Mistry PK
    Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():58. PubMed ID: 24380122
    [No Abstract]   [Full Text] [Related]  

  • 5. [Enzyme replacement therapy for lysosomal storage disorders].
    Valayannopoulos V; Brassier A; Chabli A; Caillaud C; Lemoine M; Odent T; Arnoux JB; de Lonlay P
    Arch Pediatr; 2011 Oct; 18(10):1119-23. PubMed ID: 21873040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gaucher disease: Progress and ongoing challenges.
    Mistry PK; Lopez G; Schiffmann R; Barton NW; Weinreb NJ; Sidransky E
    Mol Genet Metab; 2017; 120(1-2):8-21. PubMed ID: 27916601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysosomal storage diseases: natural history and ethical and economic aspects.
    Beutler E
    Mol Genet Metab; 2006 Jul; 88(3):208-15. PubMed ID: 16515872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating lysosomal storage disorders: What have we learnt?
    Lachmann RH
    J Inherit Metab Dis; 2020 Jan; 43(1):125-132. PubMed ID: 31140601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme replacement therapy and beyond-in memoriam Roscoe O. Brady, M.D. (1923-2016).
    Ries M
    J Inherit Metab Dis; 2017 May; 40(3):343-356. PubMed ID: 28314976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme replacement therapy for lysosomal storage disorders: successful transition from concept to clinical practice.
    Sly WS
    Mo Med; 2004; 101(2):100-4. PubMed ID: 15119106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roscoe Owen Brady: Passion for patients.
    Medin JA
    Proc Natl Acad Sci U S A; 2016 Oct; 113(42):11644-11645. PubMed ID: 27791045
    [No Abstract]   [Full Text] [Related]  

  • 12. Overcoming the Next Barriers to Successful Therapy.
    Cohen IJ; Baris H; Mistry PK; Sands MS
    Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():629. PubMed ID: 27491209
    [No Abstract]   [Full Text] [Related]  

  • 13. Enzyme replacement therapy for lysosomal storage diseases.
    Ohashi T
    Pediatr Endocrinol Rev; 2012 Oct; 10 Suppl 1():26-34. PubMed ID: 23330243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation and results of a risk-sharing scheme for enzyme replacement therapy in lysosomal storage diseases.
    Edo-Solsona MD; Vitoria-Miñana I; Poveda-Andrés JL
    Farm Hosp; 2020 Jan; 44(1):10-15. PubMed ID: 31901056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme replacement therapy for lysosomal storage diseases.
    Lachmann RH
    Curr Opin Pediatr; 2011 Dec; 23(6):588-93. PubMed ID: 21946346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The attenuated/late onset lysosomal storage disorders: Therapeutic goals and indications for enzyme replacement treatment in Gaucher and Fabry disease.
    Hollak CE; Weinreb NJ
    Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):205-18. PubMed ID: 25987174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Enzyme replacement therapy of lysosomal storage diseases].
    Germain DP; Boucly C; Carlier RY; Caudron E; Charlier P; Colas F; Jabbour F; Martinez V; Mokhtari S; Orlikowski D; Pellegrini N; Perronne C; Prigent H; Rubinsztajn R; Benistan K
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S279-91. PubMed ID: 21211680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of antibodies in enzyme treatments and therapeutic strategies.
    Bigger BW; Saif M; Linthorst GE
    Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):183-94. PubMed ID: 25987172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing novel chemical entities for the treatment of lysosomal storage disorders: an academic perspective.
    Shayman JA
    Am J Physiol Renal Physiol; 2015 Dec; 309(12):F996-9. PubMed ID: 26447223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysosomal storage disorders. Preface.
    Hollak CE
    Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):125-6. PubMed ID: 25987167
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.